LT3749353T - Nemolizumabas atopinio dermatito, pasireiškiančio vidutinio ar didelio laipsnio ekskoriacija, gydymui - Google Patents

Nemolizumabas atopinio dermatito, pasireiškiančio vidutinio ar didelio laipsnio ekskoriacija, gydymui

Info

Publication number
LT3749353T
LT3749353T LTEPPCT/IB2019/051051T LTIB2019051051T LT3749353T LT 3749353 T LT3749353 T LT 3749353T LT IB2019051051 T LTIB2019051051 T LT IB2019051051T LT 3749353 T LT3749353 T LT 3749353T
Authority
LT
Lithuania
Prior art keywords
nemolizumab
excoriation
moderate
severe
treatment
Prior art date
Application number
LTEPPCT/IB2019/051051T
Other languages
English (en)
Inventor
Nabil Kerrouche
Keiko HIROKAWA
Ryosuke MIHARA
Original Assignee
Galderma Holding SA
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Seiyaku Kabushiki Kaisha filed Critical Galderma Holding SA
Publication of LT3749353T publication Critical patent/LT3749353T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/IB2019/051051T 2018-02-09 2019-02-08 Nemolizumabas atopinio dermatito, pasireiškiančio vidutinio ar didelio laipsnio ekskoriacija, gydymui LT3749353T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
LT3749353T true LT3749353T (lt) 2025-09-25

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2019/051051T LT3749353T (lt) 2018-02-09 2019-02-08 Nemolizumabas atopinio dermatito, pasireiškiančio vidutinio ar didelio laipsnio ekskoriacija, gydymui

Country Status (23)

Country Link
US (2) US12435147B2 (lt)
EP (2) EP3749353B1 (lt)
JP (3) JP7777921B2 (lt)
CN (1) CN112040976A (lt)
AU (2) AU2019219608B2 (lt)
BR (1) BR112020016144A2 (lt)
CA (1) CA3090062A1 (lt)
CL (1) CL2020002050A1 (lt)
DK (1) DK3749353T3 (lt)
ES (1) ES3049513T3 (lt)
FI (1) FI3749353T3 (lt)
HR (1) HRP20251101T1 (lt)
IL (1) IL276524A (lt)
LT (1) LT3749353T (lt)
MX (1) MX2020008193A (lt)
PH (1) PH12020551185A1 (lt)
PL (1) PL3749353T3 (lt)
PT (1) PT3749353T (lt)
RU (1) RU2758378C1 (lt)
SG (1) SG11202007558YA (lt)
SI (1) SI3749353T1 (lt)
TW (1) TWI856006B (lt)
WO (1) WO2019155427A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
JP2008530132A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR20170134748A (ko) * 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
EP3383363B1 (en) * 2015-11-30 2021-01-06 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
AU2019219608A1 (en) 2020-08-27
FI3749353T3 (fi) 2025-09-10
RU2758378C1 (ru) 2021-10-28
JP2021512917A (ja) 2021-05-20
AU2019219608B2 (en) 2025-10-16
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
CN112040976A (zh) 2020-12-04
JP7777921B2 (ja) 2025-12-01
PL3749353T3 (pl) 2025-12-08
EP3749353B1 (en) 2025-07-30
WO2019155427A1 (en) 2019-08-15
TW202448919A (zh) 2024-12-16
PH12020551185A1 (en) 2021-05-17
TW201941800A (zh) 2019-11-01
CA3090062A1 (en) 2019-08-15
US20260008859A1 (en) 2026-01-08
ES3049513T3 (en) 2025-12-17
SI3749353T1 (sl) 2025-10-30
DK3749353T3 (da) 2025-09-01
EP4644424A3 (en) 2026-01-14
HRP20251101T1 (hr) 2025-11-21
EP4644424A2 (en) 2025-11-05
MX2020008193A (es) 2020-11-24
BR112020016144A2 (pt) 2020-12-15
US20200385476A1 (en) 2020-12-10
CL2020002050A1 (es) 2020-12-11
US12435147B2 (en) 2025-10-07
JP2023182632A (ja) 2023-12-26
AU2026200182A1 (en) 2026-01-29
EP3749353A1 (en) 2020-12-16
SG11202007558YA (en) 2020-09-29
PT3749353T (pt) 2025-10-14
IL276524A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
MX384240B (es) Bacterias probioticas recombinantes.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
PL3609497T3 (pl) Niraparyb, octan abirateronu i prednizon do leczenia nowotworu złośliwego prostaty
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
DK3273797T3 (da) Sammensætning til at inhibere gram-positive, patogene bakterier
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
LT3554501T (lt) Deksmedetomidinas arba medetomidinas, skirti naudoti gydant naminių gyvūnų atsiskyrimo nerimą
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
LT3749353T (lt) Nemolizumabas atopinio dermatito, pasireiškiančio vidutinio ar didelio laipsnio ekskoriacija, gydymui
DK4009942T3 (da) Forbindelse til kombinationsbehandling
MX2020000625A (es) Metodos para tratar trastornos microvasculares autoinmunes.
HUE053089T2 (hu) Migrén kezelése acetil-leucinnal
LT3519050T (lt) Kompozicijos, skirtos oftalmologinių būklių gydymui
IT201700086482A1 (it) Composizione per il trattamento della vaginosi batterica
DK3541777T3 (da) Sammensætninger til behandling af atopisk dermatitis
LT3482761T (lt) Kompozicijos, apimančios kromoglicino rūgštį, skirtos dermatito gydymui